Immunology wars: Monoclonal antibodies

nature video
11 followers
Sep 5, 2023
Our immune systems are at war with cancer. This animation reveals how monoclonal antibodies can act as valuable reinforcements to shore up our defences – and help battle cancer.
You can find more on this topic at http://www.nature.com/milestones/antibodies
Nature Research has full responsibility for all editorial content, including Nature Video content. This content is editorially independent of sponsors.
Sign up for the Nature Briefing: An essential round-up of science news, opinion and analysis, free in your inbox every weekday. https://go.nature.com/371OcVF
When it comes to treating diseases like cancer,
modern medicine has an impressive arsenal.
And one of its most versatile weapons are Y-shaped proteins
called monoclonal antibodies.
Our immune systems already produce their own antibodies.
They come in billions of variations,
each matching a specific target,
such as a particular toxin, bacteria or virus.
When they bind to their target, they send a signal.
This bacterium is now marked for destruction.
These naturally produced antibodies are pretty effective.
But in the 1970s, scientists figured out how to mass produce them.
They can take any specifically targeted antibody
and make huge numbers of identical clones.
Which means you can produce monoclonal antibodies
for almost any disease you can think of.
Which brings us on to cancer.
Mutated cells that start growing out of control can be deadly.
But the body's immune system isn't defenceless.
Meet the CTL.
It's a type of white blood cell that can detect infected or mutated cells.
And when it finds one, it secretes toxic molecules
that initiate a self-destruct sequence.
But the CTLs do sometimes need to be reined in.
If they get over-enthusiastic,
the immune system can start causing collateral damage,
attacking healthy cells.
Fortunately, the CTLs can be turned off
by activating a molecule called PD-1.
The trouble with having an off switch is that cancer cells can exploit it.
Many cancer cells protect themselves with a counter-receptor called PD-L1.
This is where monoclonal antibodies come in.
Scientists can use one of two types.
One that binds the PD-1 molecule,
or another that goes for PD-L1.
Thanks to the monoclonal antibodies,
all of the CTLs are fully activated and can blast away the cancer.
This is just one way that monoclonal antibodies can be used.
They've already proven effective against a whole range of cancers,
and yet more are still being developed.
With their ability to be targeted at specific diseases,
monoclonal antibodies are turning out to be a game-changer,
and one of our most effective weapons in the fight against cancer.
